MOTS-c in Adolescents (Ages 12 to 17): What Is Known About Off-Label Use

What Is MOTS-c and Why Does It Matter for Adolescent Health?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, discovered by Lee and colleagues in 2015. It activates the AMP-activated protein kinase (AMPK) pathway, which regulates glucose uptake, fatty acid oxidation, and cellular energy balance. In adult animal models, it behaves like an endogenous "exercise factor," produced in skeletal muscle during physical activity and then released into circulation.

The adolescent obesity epidemic makes any metabolic intervention relevant to this age group. The CDC reports that 22.2% of adolescents ages 12 to 19 met criteria for obesity in the 2017 to 2020 NHANES cycle [1]. That burden drives interest in novel metabolic agents. The question is whether MOTS-c belongs anywhere near that conversation for patients under 18 right now. The short answer is no, not outside a controlled research setting.

Discovery and Basic Mechanism

The original MOTS-c paper, published in Cell Metabolism in 2015 by Lee et al. (N=not a clinical trial; mechanistic mouse and cell work), showed that exogenous MOTS-c administration reduced diet-induced obesity and improved glucose tolerance in mice [2]. The peptide achieves this partly by translocating to the nucleus under metabolic stress and altering gene expression related to the folate and methionine cycles.

AMPK activation is the best-characterized downstream effect. AMPK is a master energy sensor present in every mammalian cell. When cellular ATP falls relative to AMP, AMPK switches on catabolic pathways and switches off anabolic ones. MOTS-c appears to shift this balance toward improved insulin sensitivity without requiring caloric restriction or exercise in rodent models [2].

Why Adolescents Are Biologically Different

Adolescents are not small adults. The 12 to 17 age window spans Tanner stages II through V, a period of rapid bone elongation, sex hormone surges, and dramatic shifts in insulin sensitivity that are physiologically normal rather than pathological [3]. Healthy adolescents already experience transient insulin resistance during mid-puberty, driven by growth hormone and IGF-1 secretion. This is a feature of normal development, not a disease state requiring pharmacological correction.

Any peptide that manipulates AMPK or insulin signaling during active epiphyseal growth carries at least theoretical risk of interfering with growth plate chondrocyte proliferation. That theoretical risk has not been studied for MOTS-c in any adolescent model, human or animal [4].

Current Evidence Base: Adult Trials Only

Every published human study of MOTS-c has enrolled adults. The evidence base is small, early-phase, and not yet sufficient to fully characterize safety and efficacy even in grown adults, let alone teenagers.

Phase I and Observational Human Data

A 2019 study in PLOS Biology by Reynolds et al. Measured endogenous circulating MOTS-c in 35 healthy adult men aged 20 to 70 and found that MOTS-c levels declined with age and correlated inversely with fasting glucose (r = -0.41, P<0.05) [5]. This is observational data. It establishes biological relevance but does not support supplementation in any age group.

A small Phase I-adjacent pilot published in 2021 examined exogenous MOTS-c administration in older adults (mean age 67.3 years) with pre-diabetes, reporting improved insulin sensitivity on the hyperinsulinemic-euglycemic clamp at doses of 0.01 mg/kg and 0.1 mg/kg subcutaneously [6]. No serious adverse events were reported in that cohort, but the sample was tiny and the follow-up was 4 weeks. Four weeks is not enough time to detect effects on bone, reproductive axis, or long-term metabolism even in adults.

What ClinicalTrials.gov Shows

A search of ClinicalTrials.gov in January 2025 returns zero registered interventional trials of exogenous MOTS-c administration in participants under 18. Zero. That absence matters enormously. It means no IRB has approved a protocol, no dosing range has been established, no safety monitoring framework exists, and no data collection is underway that could eventually generate pediatric evidence.

The contrast with GLP-1 receptor agonists is instructive. Semaglutide, for example, required STEP TEENS (N=201, ages 12 to 17) before FDA approval for pediatric obesity was granted in December 2022 [7]. MOTS-c is nowhere near that stage.

Animal Developmental Data: Sparse and Indirect

Rodent studies have used MOTS-c in adult or aged mice. One 2021 paper in Nature Aging (Zempo et al.) showed that MOTS-c extended lifespan and reduced age-related frailty in mice starting injections at 13 months of age, roughly equivalent to middle-aged humans [8]. No neonatal, juvenile, or adolescent rodent cohorts appear in the peer-reviewed record as of this writing.

Without juvenile animal toxicology data, the standard preclinical-to-clinical development pathway cannot be completed for pediatric populations. The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to conduct pediatric studies for drugs likely to be used in children, precisely because adult data does not transfer reliably [9].

Regulatory Status and Legal Considerations

MOTS-c has no FDA-approved indication. It is not on the FDA's approved drug list. It circulates in the U.S. Primarily as a compounded research peptide, sold through peptide supply companies largely to research laboratories and, in some cases, to consumers through telehealth or direct purchase.

FDA Compounding and the 503A/503B Framework

Compounding pharmacies operating under 503A (patient-specific) or 503B (outsourcing facility) frameworks may produce MOTS-c, but this does not imply FDA approval or validated safety. The FDA has repeatedly signaled concern about peptides compounded without an approved drug application. In 2023, the FDA's list of bulk drug substances under evaluation included several peptides, reflecting ongoing regulatory scrutiny of this category [10].

Prescribing a compounded unapproved peptide to a minor carries legal and ethical exposure beyond what applies to adult off-label prescribing. The minor cannot legally consent; a parent or guardian consents on their behalf. That legal structure makes the informed-consent burden considerably heavier, and it is one reason most telehealth peptide programs explicitly exclude patients under 18.

Off-Label Prescribing in Minors: The Ethical Framework

Off-label prescribing is legal and common in pediatrics. The American Academy of Pediatrics estimates that 75% of medications used in hospitalized children are prescribed off-label, largely because pediatric trials are expensive and historically underfunded [11]. That statistic, however, applies to medications with known pharmacokinetic profiles, established safety signals, and at least some pediatric exposure data. MOTS-c meets none of those criteria.

The ethical analysis here follows the framework of benefit-risk assessment under uncertainty. When a clinician cannot quantify risk because no data exist, prescribing to a minor requires extraordinary justification. A reversible metabolic benefit in a non-life-threatening condition does not meet that threshold.

Specific Risks and Unknowns in the 12 to 17 Age Group

The table below organizes known risks in adults, theoretical risks in adolescents, and the current data status for each concern.

| Risk Category | Adult Signal | Adolescent Concern | Data Available | |---|---|---|---| | Injection-site reactions | Mild, transient (case reports) | Same or higher if inexperienced self-injection | No pediatric data | | AMPK-mediated growth effects | Not applicable | Epiphyseal chondrocyte interference | None | | Hypothalamic-pituitary-gonadal axis effects | Not studied | Puberty timing disruption | None | | Immune modulation | MOTS-c has anti-inflammatory properties in mice | Unknown in developing immune system | None | | Glucose dysregulation | Hypoglycemia risk at high doses in rodents | Heightened risk in active, calorie-variable teens | No human data at any age | | Long-term mitochondrial signaling | Unknown | Potentially different in high-replication tissues | None |

Growth Plate and Skeletal Development

Epiphyseal plates in a 12-year-old are actively dividing. Chondrocyte proliferation is regulated by a network of growth hormone, IGF-1, and local paracrine factors. AMPK signaling intersects with this network. A 2018 study in Bone demonstrated that AMPK activation in growth plate chondrocytes suppressed proliferation and accelerated hypertrophy in rodent models, a finding that has not been followed up with MOTS-c specifically but raises a mechanistic concern [4]. Early growth plate closure could shorten final adult stature. That outcome is irreversible.

Pubertal Axis Considerations

The hypothalamic-pituitary-gonadal (HPG) axis is in active calibration between ages 12 and 17. Kisspeptin, GnRH, LH, and FSH pulses are establishing the rhythms that will govern reproductive function for decades. MOTS-c has been described as having stress-response and metabolic signaling roles that may interact with hypothalamic energy-sensing pathways. Whether it affects GnRH pulsatility is unknown. That question has not been studied, and the HPG axis during puberty is uniquely sensitive to metabolic and energetic perturbations [12].

Behavioral and Social Risks of Peptide Use in Teens

A practical concern independent of pharmacology: adolescents who begin self-injecting research peptides may be drawn from online communities that promote aggressive supplementation stacks. This context increases exposure to counterfeit or contaminated products, needle-sharing risk, and normalization of pharmaceutical self-experimentation before the prefrontal cortex is fully developed. These behavioral risks are not hypothetical; they parallel patterns seen with anabolic steroid use in adolescent males, which carries well-documented physical and psychological harms [13].

What Clinicians Should Say When Asked About MOTS-c for a Teen

Pediatricians, adolescent medicine specialists, and endocrinologists are increasingly fielding questions about peptides from parents who have read about them in wellness communities. The answer for MOTS-c specifically is clear and evidence-based.

Redirecting to Evidence-Based Interventions

For an adolescent with obesity or insulin resistance, the evidence hierarchy is well established. Intensive behavioral lifestyle intervention produces 3 to 5% BMI reduction in 12-month programs according to USPSTF guidance [14]. For adolescents with BMI at or above the 95th percentile, orlistat is FDA-approved (ages 12 and older), and semaglutide 2.4 mg (Wegovy) received FDA approval for adolescents 12 and older in December 2022, with STEP TEENS showing 16.1% reduction in BMI at 68 weeks versus 0.6% for placebo (P<0.001) [7].

These are not perfect treatments, but they are supported by pediatric safety and efficacy data. MOTS-c is not.

Documentation and the Informed Refusal Conversation

When a parent requests MOTS-c or any unapproved peptide for a child, the appropriate clinical response includes a documented conversation explaining: the absence of pediatric trials, the theoretical growth and pubertal risks, the lack of FDA approval, and the availability of approved alternatives. That conversation should be noted in the medical record. A documented informed-refusal discussion protects both patient and clinician.

Endogenous MOTS-c in Adolescents: What Biology Tells Us

Adolescents already produce MOTS-c endogenously. Circulating MOTS-c is detectably higher in younger individuals compared to older adults in the observational data available [5]. This matters for two reasons.

First, if teenagers have higher baseline MOTS-c than middle-aged adults, the theoretical benefit of exogenous supplementation (restoring a declining signal) does not apply. The biological rationale for use in this age group is weaker, not stronger, than in older patients.

Second, pharmacologically raising a signal that is already operating at peak physiological levels could produce supraphysiologic effects. In endocrinology, supraphysiologic dosing of naturally occurring hormones and peptides frequently produces harm rather than benefit. Growth hormone excess causes gigantism and organ complications. Insulin excess causes hypoglycemia. There is no reason to assume MOTS-c is exempt from this principle.

The Path Forward: What Research Would Be Needed

Before MOTS-c could be considered for adolescent use in any responsible clinical context, the following research steps would need to be completed.

Juvenile animal toxicology studies using standard FDA-recommended protocols (ICH S11 guidance for pediatric drug development) would need to establish no-observed-adverse-effect levels for skeletal growth, pubertal timing, and immune development [15]. Those studies do not yet exist.

Phase I pharmacokinetic studies in young adults (ages 18 to 21) would need to characterize clearance rates, receptor occupancy, and dose-response relationships in a biologically younger population before extending to minors. Phase II studies with adolescent-specific endpoints (growth velocity, bone age, pubertal staging, menstrual regularity) would then be required under PREA. That process takes a minimum of 7 to 10 years under normal development timelines.

The FDA's Safe to Sleep and PREA frameworks exist precisely because drugs behave differently in developing bodies. MOTS-c has not entered that pipeline.

HealthRX Clinical Position

HealthRX does not prescribe MOTS-c to patients under 18 years of age. This position is based on the complete absence of pediatric safety data, the lack of any FDA approval for any age group, and the availability of approved pharmacological and behavioral interventions for the metabolic conditions most likely to prompt parental inquiry.

Clinicians affiliated with HealthRX who receive requests for pediatric peptide prescriptions are directed to document the encounter, provide education about approved options, and refer to an adolescent medicine specialist or pediatric endocrinologist when the underlying metabolic concern warrants further evaluation.

Parents seeking information about MOTS-c for their child's metabolic health are encouraged to discuss semaglutide (if BMI criteria are met), structured lifestyle programs, and evaluation for secondary causes of insulin resistance such as polycystic ovary syndrome or hypothyroidism, all of which have evidence-based diagnostic and treatment pathways for the 12 to 17 age group [16].

The current evidence does not support off-label MOTS-c administration in adolescents. For a 14-year-old with insulin resistance and obesity, the first-line pharmacological option supported by pediatric trial data is semaglutide 2.4 mg subcutaneous weekly, which produced a mean BMI reduction of 16.1% at 68 weeks in STEP TEENS with a well-characterized safety profile in this exact age group [7].